Pharmacyte Biotech Stock Performance

PMCB Stock  USD 0.77  0.07  10.00%   
The company holds a Beta of 2.75, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PharmaCyte Biotech will likely underperform. PharmaCyte Biotech right now holds a risk of 9.94%. Please check PharmaCyte Biotech potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if PharmaCyte Biotech will be following its historical price patterns.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days PharmaCyte Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong fundamental indicators, PharmaCyte Biotech is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor
1:1550
Last Split Date
2021-07-12
1
PMCB Stock Jumps 25 percent After Company Sells Stake In Femasys - MSN
12/02/2025
2
Disposition of 16875 shares by Abecassis Michael M of PharmaCyte Biotech at 1.02 subject to Rule 16b-3
12/12/2025
3
PharmaCyte Biotech Delays Quarterly Report Filing - TipRanks
12/15/2025
4
Will PharmaCyte Biotech Inc. stock benefit from infrastructure spending - Weekly Investment Recap High Return Stock Watch Alerts - ulpravda.ru
12/19/2025
5
Acquisition by Schechter Jonathan of 20000 shares of PharmaCyte Biotech at 0.7776 subject to Rule 16b-3
01/05/2026
6
Acquisition by Schechter Jonathan of 20000 shares of PharmaCyte Biotech at 0.7904 subject to Rule 16b-3
01/06/2026
7
Acquisition by Schechter Jonathan of 20000 shares of PharmaCyte Biotech at 0.8436 subject to Rule 16b-3
01/07/2026
8
Dow Update Is PharmaCyte Biotech Inc vulnerable to short sellers - Market Risk Summary Verified Trade Idea Suggestions - baoquankhu1.vn
02/05/2026
Begin Period Cash Flow50.2 M
Total Cashflows From Investing Activities-7 M

PharmaCyte Biotech Relative Risk vs. Return Landscape

If you would invest  88.00  in PharmaCyte Biotech on November 8, 2025 and sell it today you would lose (18.00) from holding PharmaCyte Biotech or give up 20.45% of portfolio value over 90 days. PharmaCyte Biotech is currently generating 0.0211% in daily expected returns and assumes 9.9442% risk (volatility on return distribution) over the 90 days horizon. In different words, 89% of stocks are less volatile than PharmaCyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days PharmaCyte Biotech is expected to generate 4.54 times less return on investment than the market. In addition to that, the company is 12.14 times more volatile than its market benchmark. It trades about 0.0 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

PharmaCyte Biotech Target Price Odds to finish over Current Price

The tendency of PharmaCyte Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.77 90 days 0.77 
about 74.75
Based on a normal probability distribution, the odds of PharmaCyte Biotech to move above the current price in 90 days from now is about 74.75 (This PharmaCyte Biotech probability density function shows the probability of PharmaCyte Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.75 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, PharmaCyte Biotech will likely underperform. Additionally PharmaCyte Biotech has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   PharmaCyte Biotech Price Density   
       Price  

Predictive Modules for PharmaCyte Biotech

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PharmaCyte Biotech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PharmaCyte Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.040.7710.71
Details
Intrinsic
Valuation
LowRealHigh
0.040.7110.65
Details
Naive
Forecast
LowNextHigh
0.010.4410.39
Details

PharmaCyte Biotech Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. PharmaCyte Biotech is not an exception. The market had few large corrections towards the PharmaCyte Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PharmaCyte Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PharmaCyte Biotech within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.17
β
Beta against Dow Jones2.75
σ
Overall volatility
0.12
Ir
Information ratio -0.01

PharmaCyte Biotech Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PharmaCyte Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PharmaCyte Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
PharmaCyte Biotech had very high historical volatility over the last 90 days
PharmaCyte Biotech has some characteristics of a very speculative penny stock
PharmaCyte Biotech currently holds about 82.23 M in cash with (2.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: Dow Update Is PharmaCyte Biotech Inc vulnerable to short sellers - Market Risk Summary Verified Trade Idea Suggestions - baoquankhu1.vn

PharmaCyte Biotech Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PharmaCyte Stock often depends not only on the future outlook of the current and potential PharmaCyte Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PharmaCyte Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding7.3 M
Cash And Short Term Investments15.5 M

PharmaCyte Biotech Fundamentals Growth

PharmaCyte Stock prices reflect investors' perceptions of the future prospects and financial health of PharmaCyte Biotech, and PharmaCyte Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PharmaCyte Stock performance.

About PharmaCyte Biotech Performance

By analyzing PharmaCyte Biotech's fundamental ratios, stakeholders can gain valuable insights into PharmaCyte Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PharmaCyte Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PharmaCyte Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 148.25  140.84 
Return On Tangible Assets 0.51  0.54 
Return On Capital Employed(0.08)(0.08)
Return On Assets 0.50  0.53 
Return On Equity 0.68  1.06 

Things to note about PharmaCyte Biotech performance evaluation

Checking the ongoing alerts about PharmaCyte Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PharmaCyte Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
PharmaCyte Biotech had very high historical volatility over the last 90 days
PharmaCyte Biotech has some characteristics of a very speculative penny stock
PharmaCyte Biotech currently holds about 82.23 M in cash with (2.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: Dow Update Is PharmaCyte Biotech Inc vulnerable to short sellers - Market Risk Summary Verified Trade Idea Suggestions - baoquankhu1.vn
Evaluating PharmaCyte Biotech's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate PharmaCyte Biotech's stock performance include:
  • Analyzing PharmaCyte Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PharmaCyte Biotech's stock is overvalued or undervalued compared to its peers.
  • Examining PharmaCyte Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating PharmaCyte Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PharmaCyte Biotech's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of PharmaCyte Biotech's stock. These opinions can provide insight into PharmaCyte Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating PharmaCyte Biotech's stock performance is not an exact science, and many factors can impact PharmaCyte Biotech's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for PharmaCyte Stock analysis

When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Transaction History
View history of all your transactions and understand their impact on performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities